Latest Press Releases
September 28, 2023
AnHeart Therapeutics Appoints Charlotte Arnold as Chief Corporate Affairs Officer
September 7, 2023
Latest News Articles
February 2, 2023
Genome Web
Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug
August 23, 2022
Endpoints New
August 5, 2022
Cancer Network
FDA Grants Breakthrough Therapy Designation to Taletrectinib for ROS1+ Non–Small Cell Lung Cancer
On November 8, 2022, Dr. Ross Camidge, Dr. Misako Nagasaka and Janet Freeman-Daily, the ROS1ders co-founder discussed the current and future treatment landscape including taletrectinib for ROS1+ NSCLC.
On June 7, 2022, Dr. Wei Li, Dr. Caicun Zhou, Dr. Ross Camidge, and Dr. Misako Nagasaka discussed taletrectinib TRUST-I interim data in ROS1+ NSCLC patients as published at ASCO2022.
On June 3, 2023, Dr. David Reardon, Dr. Fabio Iwamato, and Dr. Nicole Willmarth discussed the current and future treatment landscape in IDH-mutant glioma.
